

Uterine size and volume are associated with higher live birth rate in patients undergoing assisted reproduction technology

A prospective cohort study

Hong Gao, MD^{a,b}, Dong-e Liu, MM^c, Yumei Li, MD^c, Jing Tang, MM^c, Xinrui Wu, MD^b, Hongzhan Tan, MD, PhD^{b,*}

Abstract

To investigate how uterine size and volume are associated with live birth rate in patients undergoing assisted reproduction technology.

This prospective cohort study was conducted at the Reproductive Medicine Centre from January 2010 to May 2017. Multivariate binary logistic regression was used to evaluate the relations between uterine size, total volume, and live birth outcomes, after they were adjusted for the main influencing factors.

A total of 7320 women of clinical pregnancy were enrolled. Compared with uterine lengths of 50 to 59 mm (referent), women with uterine lengths ≥ 60 mm had a lower live birth rate (RR = 1.541). Compared with uterine widths of ≥ 50 mm (referent), women with uterine widths < 30 mm had a lower live birth rate (RR = 1.430). Compared with uterine anteroposterior diameters of < 30 mm (referent), women with uterine anteroposterior diameters ≥ 50 mm had a lower live birth rate (RR = 1.636). Compared with uterine volumes of 30 to 49 mL (referent), women with volumes < 30 mL and ≥ 70 mL had lower live birth rates (RR = 1.368 and 1.742, respectively).

Our findings indicate that uterine sizes and volumes that were too large or too small reduced the live birth rate.

Abbreviations: ART = assisted reproduction technology, E₂ = estradiol, FSH = follicle-stimulating hormone, HCG = human chorionic gonadotropin, HMG = human menopausal gonadotropin, ICSI = intracytoplasmic sperm injection, IVF = in vitro fertilization, LH = luteinizing hormone, RR = relative risk.

Keywords: ART, female infertility, live birth rate, uterine size, uterine volume

1. Introduction

For patients and gynaecologists, the most important objective is having the birth of at least one live-born healthy baby. A recent study reported that 803,792 babies were born worldwide

following ART from 2008 through 2010, and a total of >4,461,309 ART cycles were initiated.^[1] From these results, we found that not every cycle of ART treatment was successful, and the birth rate was not high. Live birth outcomes may be influenced by many factors, such as maternal age,^[2–4] response to ovarian stimulation,^[5–7] and embryo parameters.^[8–10] However, there have been few studies addressing the association between the uterus and live birth outcomes following ART.

The uterus has the most basic and important function, which is to nourish and protect the developing foetus during pregnancy until birth. Accordingly, uterine size, volume, and endometria all affect the implantation of the embryo and the growth and development of the foetus. At present, existing studies examine the relationships between congenital uterine anomalies and ART outcome,^[11–13] uterine length and IVF outcome,^[14] and uterine immune profiling, and live birth rate.^[15] Our previous studies have shown that the size and volume of the uterus can affect clinical pregnancy rates in ART patients.^[16] The optimal uterine size and volume led to the highest clinical pregnancy rates. It is well known that pregnant women still have a long way to go from clinical pregnancy to live birth. During this period, the fetus lives in the uterus. Therefore, it is conceivable that the size and volume of the uterus are important for live-born babies. Nevertheless, studies of the relationships between uterine size (including length, width, anteroposterior diameter), and total volume and live birth outcome following ART in infertile women are rare.

We attempted to find the size and volume range of the uterus that is detrimental to the growth and development of the foetus in

Editor: Meixia Lu.

HG and DEL are the joint first authorship.

This work was supported by the Excellent Young Talents Fund Program of Education Department of Hunan Province in China [No. (2019)90-18B277].

The authors have no conflicts of interest to disclose.

^a School of Nursing, University of South China, Hengyang, ^b Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, ^c Reproductive Medicine Center, Xiangya Hospital, Central South University, Changsha, Hunan, China.

* Correspondence: Hongzhan Tan, Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, No. 110 Xiangya Road, Changsha, Hunan 410008, China (e-mail: tanhz99@qq.com).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Gao H, Liu De, Li Y, Tang J, Wu X, Tan H. Uterine size and volume are associated with higher live birth rate in patients undergoing assisted reproduction technology: a prospective cohort study. *Medicine* 2019;98:47(e17966).

Received: 19 June 2019 / Received in final form: 10 October 2019 / Accepted: 11 October 2019

<http://dx.doi.org/10.1097/MD.0000000000017966>

the uterus. We hypothesized that uterine size and volume are associated with the live birth rate in infertile Chinese Han women.

2. Materials and methods

This prospective cohort study was conducted among women undergoing ART treatments in the Reproductive Medicine Centre, all of whom provided informed consent. This study was performed in accordance with all relevant guidelines and regulations. The Reproductive Medicine Centre of Xiangya Hospital is an important integrated ART treatment centre in south China that drew patients from all over China.

2.1. Study population

All women presenting to the Reproductive Medicine Centre, Xiangya Hospital of Central South University, Hunan, China, who were planned for ART treatments and who signed the informed consent were enrolled in our study from January 2010 to May 2016. Exclusion criteria included women with congenital uterine malformation, uterine septum, uterus duplex, uterine cancer, rudimentary horn of uterus, hysteroomyoma, adenomyosis, intrauterine adhesions or all of the uteri after surgical operation. All women with clinical pregnancy (ultrasound confirmed an intrauterine gestational sac) by ART treatments were included in our final analysis.

2.2. Data collection

All data of the subjects were recorded by the electronic medical records (Haitai, Nanjing, China) of Xiangya Hospital Central South University. The subjects were followed up for 12 months with the last visit in May 2017. All subjects were interviewed face to face, collecting their data, including age, social-demographics, history of assisted reproductive technology, and treatment outcomes of assisted reproductive technology. Height, weight, and BMI were measured. Pre-cycle uterine size was measured by transvaginal ultrasonography. Information about artificial insemination and live birth outcomes was collected. The data recorders included attending gynaecologists, fellows and nurses.

2.3. Uterine size measurements

The uterine size of all patients was measured by transvaginal ultrasonic image examination. All ultrasonic scans were performed with 5.0 to 8.0 MHz scanners (DC – 6 Expert, Mindray) by gynaecologists specialized in gynaecological ultrasonography. In our study, the three most senior gynaecologists who were specialists in gynaecological ultrasonography took the uterine measurements. By 2011, they had at least 16 years of work experience; so, the uterine measurement results were reliable. The following parameters were analyzed: uterine longitudinal diameter (length), transverse diameter (width), and anteroposterior diameter. The longitudinal diameter was measured from the cervical internal os to the fundus in the sagittal plane; the transverse diameter was measured by the maximum diameter from the right to the left side of the uterine corpus in the transverse plane; the anteroposterior diameter was measured from the anterior serosa to the posterior serosa at the point at which the uterus appeared at its thickest and perpendicular to the endometrial line in the sagittal plane.^[17] Uterine volume was

calculated according to the formula for ellipsoid bodies: $V = \text{longitudinal diameter} \times \text{anteroposterior diameter} \times \text{transverse diameter} \times 0.5233$.^[18]

2.4. ART treatment

The protocols of ovarian stimulation mainly included a long, short, antagonist, and mini-stimulation protocol.

Long protocol: on day 21 of the menstrual cycle, patients were injected with gonadotropin releasing hormone agonist (triptorelin), 0.05 to 0.1 mg/day, and continued treatment until the day of human chorionic gonadotropin (HCG) release. After reaching the standards of downregulation (FSH < 5 IU/L, E2 < 50 pg/mL, LH < 5 IU/L, follicular diameter < 8 mm, and endometrium < 5 mm), gonadotropin (Gn) stimulation was started, human menopausal gonadotropin (HMG, Menogon; Ferring) or recombinant FSH (rFSH, Gonal-f; Merck Serono, Darmstadt, Germany) 150 to 300 IU/day. The dose of gonadotropin was adjusted according to follicular growth, endometrial thickness, and serum sex hormone levels. After 5 days, the growth and development of the follicle and endometrium were monitored daily or on alternate days with transvaginal ultrasonography. When B ultrasonography showed the mean diameter of 1 to 2 follicles ≥ 20 mm, or 2 and over follicular diameter ≥ 18 mm, then patients were injected with HCG (Livzon, Guangdong, China) at 10,000 IU.

Short protocol: on day 1 to 3 of the menstrual cycle, patients were injected with gonadotropin releasing hormone agonist (triptorelin), 0.05 to 0.1 mg/day, and continued treatment until the day of HCG. On day 3, Gn stimulation was started with HMG or rFSH 225 to 300 IU/day. Follow-up treatment was the same as the long protocol.

Antagonist protocol: on day 2 of the menstrual cycle, patients were injected with rFSH daily. After reaching at least one standard (1 and over follicular diameter ≥ 14 mm, E2 ≥ 600 pg/mL, and LH ≥ 10 IU/L), cetrorelix (Cetrotide; Merck Serono) treatment was started, 0.25 mg/day. Then, the antagonist and rFSH were used every day until the day of HCG release.

Ovum pickup was conducted 36 to 38 h after HCG injection under transvaginal ultrasonography guidance.

The oocytes were evaluated in metaphase II. The selection of fertilization methods relied on the patients' partner's condition and mainly included IVF and ICSI. The quality of the embryo was assessed according to multinucleation, the degree of fragmentation and the number of blastomeres.^[19] The number of embryo transfers was not more than 3. Types of embryo transfer included fresh and frozen-thawed embryos.

2.5. Outcome measures

Live birth means the birth of at least one live-born baby per initiated cycle or embryo transfer procedure, and all the other adverse pregnancy outcomes belong to non-live birth.

2.6. Statistical analysis

All data were managed and analyzed using the statistical package for social sciences (SPSS) software version 17.0 (SPSS Inc 2008, Chicago, IL) and Excel (Microsoft Corp., Redmond, WA). Measurement data were described by mean \pm standard deviation (SD), and enumeration data were described by number (percentage). Multivariate binary logistic regression was used

Table 1
Variable assignment in the multivariate logistic regression analysis.

Risk factors	Variable names	Assignment statements*
Number of previous ART treatments	X1	1 = 1, 2 = 2, 3 = ≥ 3
No. of antral follicles	X2	1 = <5, 2 = 5~, 3 = 10~, 4 = ≥ 15
Uterine length (mm)	X3	1 = <40, 2 = 40~, 3 = 50~, 4 = ≥ 60
Uterine width (mm)	X4	1 = <30, 2 = 30~, 3 = 40~, 4 = ≥ 50
Uterine anteroposterior diameter (mm)	X5	0 = <30, 2 = 30~, 3 = 40~, 4 = ≥ 50
Uterine volume (mL)	X6	1 = <30, 0 = 30~, 3 = 50~, 4 = ≥ 70
Stimulation protocol	X7	0 = long protocol, 1 = short protocol, 2 = antagonist protocol
Endometrial thickness before embryo transfer (mm)	X8	1 = <8, 2 = 8~, 3 = 10~, 4 = ≥ 12
Total no. of transferred embryos	X9	1 = 1, 0 = 2, 2 = 3
The quality of transferred embryos [†]	X10	1 = I, 2 = II, 3 = III
Live birth outcomes	Y	1 = non-live birth, 0 = live birth

* For X1 to X10, the group with the highest live birth rate was selected as the reference group, all of the members of which were assigned "0"; all these variables were used as dummy variables in multivariate logistic regression.

[†] The quality of transferred embryos: I is the best quality embryo, followed by II and III.

to evaluate the relations between uterine size, total volume, and live birth outcomes, after they were adjusted for the main influencing factors. All *P* values corresponded to two-sided tests; *P* < .05 was considered statistical significance. The variable assignment in the multivariate logistic regression analysis is shown in Table 1.

2.7. Ethical approval

The study was approved by the Ethics Committee of Xiangya Hospital of Central South University.

3. Results

3.1. General information

Among the 8034 patients included in the study, 714 (8.9%) were lost to follow-up, and a total of 7320 women were included in this study. Live birth outcomes include live birth [5523 (75.5%)] and non-live birth [1797 (24.5%)]. Baseline clinical and demographic characteristics of the infertile Chinese Han women were shown in Table 2.

3.2. Uterine length and live birth

We analyzed the relation between uterine length and live birth. In multivariate analysis, the determination of the influencing factors was through single factor analysis and through the multiple collinearity among influencing factors. The main influencing factors were number of previous ART treatments, Number of antral follicles, stimulation protocol, endometrial thickness before embryo transfer, total number of transferred embryos and the quality of transferred embryos. Table 3 shows that compared with uterine lengths of 50 to 59 mm (referent), women with uterine lengths ≥ 60 mm had a lower live birth rate (RR = 1.541), and there was no significant difference in the live birth rate in women with uterine lengths 40 to 49 mm and <40 mm.

3.3. Uterine width and live birth

Adjusted for number of previous ART treatments, number of antral follicles, stimulation protocol, endometrial thickness before embryo transfer, total number of transferred embryos

and the quality of transferred embryos, live birth was associated with uterine width (Table 4). Compared with women with uterine widths ≥ 50 mm (referent), women with uterine widths <30 mm had a lower live birth rate (RR = 1.430), and women with uterine widths of 30 to 39 mm and 40 to 49 mm did not have significantly different live birth rates.

3.4. Uterine anteroposterior diameter and live birth

Table 5 shows the data for the relation between uterine anteroposterior diameter and live birth following clinical pregnancy in infertile Chinese Han women. In multivariate analysis, the determination of the influencing factors was through single factor analysis and through the multiple collinearity among influencing factors. The main influencing factors were number of previous ART treatments, total number of transferred embryos, and the quality of transferred embryos. Compared with uterine anteroposterior diameters of <30 mm (referent), women with uterine anteroposterior diameters ≥ 50 mm had a lower live birth rate (RR = 1.636), and women with uterine anteroposterior diameters 30 to 39 mm and 40 to 49 mm did not have significantly different live birth rates.

3.5. Uterine volume and live birth

The relation between uterine volume and live birth outcome was statistically significant (Table 6). In multivariate analysis, the determination of the influencing factors was through single factor analysis and through the multiple collinearity among influencing factors. The main influencing factors were number of previous ART treatments, number of antral follicles, stimulation protocol, endometrial thickness before embryo transfer, total number of transferred embryos, and the quality of transferred embryos. Compared with uterine volumes of 30 to 49 mL (referent), women with volumes <30 and ≥ 70 mL had lower live birth rates (RR = 1.368 and 1.742, respectively), and women with volumes 50 to 69 mL did not have significantly different live birth rate.

4. Discussion

The main new contribution of our study is the assessment of the relationship between uterine size, volume, and live birth outcome. The study has 4 major findings. First, women with uterine lengths

Table 2
Demographic and clinical characteristics of 7320 infertile women (mean \pm SD or N [%]).

	Live birth	Nonlive birth	P
Age (years)	30.59 \pm 4.37	31.06 \pm 4.93	<.001
BMI (kg/m ²)	21.61 \pm 2.99	21.93 \pm 3.11	<.001
Number of previous ART treatments	1.73 \pm 0.98	1.82 \pm 1.06	<.001
No. of antral follicles	12.89 \pm 5.96	12.74 \pm 6.13	<.001
Endometrial thickness before embryo transfer (mm)	10.52 \pm 2.10	10.36 \pm 2.10	<.001
Total no. of transferred embryos	1.98 \pm 0.27	1.96 \pm 0.33	<.001
Uterine length (mm)	50.33 \pm 6.95	50.74 \pm 7.49	.020
Uterine width (mm)	41.55 \pm 7.21	41.38 \pm 7.68	.157
Uterine anteroposterior diameter (mm)	45.95 \pm 8.46	46.98 \pm 8.75	.017
Uterine volume (mL)	51.53 \pm 19.52	53.49 \pm 23.79	<.001
Infertility diagnosis			<.001
Male factor	742 (76.73)	225 (23.27)	
Ovulation dysfunction	28 (65.12)	15 (34.88)	
Decreased ovarian reserve	18 (64.29)	10 (35.71)	
Tubal factor	3406 (75.20)	1123 (24.80)	
Endometriosis	51 (71.83)	20 (28.17)	
Polycystic ovarian syndrome	175 (76.09)	55 (23.91)	
Chromosome abnormality	7 (50.00)	7 (50.00)	
Unexplained	20 (40.00)	30 (60.00)	
Male + female factors	1076 (77.52)	312 (22.48)	
Artificial insemination technologies			.414
IVF*	4000 (75.23)	1317 (24.77)	
ICSI†	1176 (76.96)	352 (23.04)	
IVF + ICSI	348 (76.65)	106 (23.35)	
IUI‡	18 (85.71)	3 (14.29)	
Stimulation protocol			<.001
Long protocol	2753 (77.79)	786 (22.21)	
Short protocol	465 (66.71)	232 (33.29)	
Antagonist protocol	11 (52.38)	10 (47.62)	
The quality of transferred embryos			<.001
I	5043 (76.68)	1534 (23.32)	
II	311 (75.67)	100 (24.33)	
III	54 (57.45)	40 (42.55)	
Types of transferred embryos			.403
Fresh embryo	3240 (75.79)	1035 (24.21)	
Frozen–thawed embryo	2263 (74.93)	757 (25.07)	

* IVF = in vitro fertilization.

† ICSI = intracytoplasmic sperm injection.

‡ IUI = intrauterine insemination.

of ≥ 60 mm had a lower live birth rate. Second, women with uterine widths of < 30 mm had a lower live birth rate. Third, the uterine anteroposterior diameters of ≥ 50 mm had a lower live birth rate. Finally, the uterine volumes of < 30 or ≥ 70 mL had a lower live birth rate.

In our study, women with uterine lengths of ≥ 60 mm experienced a lower likelihood of live birth. The logistic

regression demonstrates that the uterine length conferring the highest probability of live birth is closer to 50 mm. However, one study of uterine length and IVF outcomes in the United States reported that women with uterine lengths of > 90 mm had a lower live birth rate, and women with uterine lengths closer to 80 mm had the highest probability of live birth.^[14] Perhaps different races have their own reference uterine length range that is most

Table 3
Uterine length and live birth rate following ART in infertile Chinese Han women.

Uterine length (mm)	No.	No. of live birth	Live birth rate (%)	RR (95% CI)*	aRR (95% CI)†
<40	360	274	76.1	1.003 (0.777–1.296)	1.210 (0.804–1.822)
40~	3023	2290	75.8	1.023 (0.911–1.150)	1.049 (0.866–1.271)
50~	3198	2436	76.2	1 (referent)	1 (referent)
≥ 60	739	523	70.8	1.320 (1.105–1.578)	1.541 (1.161–2.047)

* RR calculated from univariate binary logistic regression.

† RR calculated from multivariate binary logistic regression adjusted for number of previous ART treatments, number of antral follicles, stimulation protocol, endometrial thickness before embryo transfer, total number of transferred embryos and the quality of transferred embryos.

Table 4**Uterine width and live birth rate following ART in infertile Chinese Han women.**

Uterine width (mm)	No.	No. of live birth	Live birth rate (%)	RR (95% CI)*	aRR (95% CI)†
<30	270	188	69.6	1.367 (1.016–1.839)	1.430 (1.050–1.948)
30~	2758	2082	75.5	1.018 (0.860–1.204)	1.082 (0.909–1.288)
40~	3279	2485	75.8	1.002 (0.850–1.181)	1.040 (0.880–1.230)
≥50	1013	768	75.8	1 (referent)	1 (referent)

* RR calculated from univariate binary logistic regression.

† RR calculated from multivariate binary logistic regression adjusted for number of previous ART treatments, number of antral follicles, stimulation protocol, endometrial thickness before embryo transfer, total number of transferred embryos and the quality of transferred embryos.

Table 5**Uterine anteroposterior diameter and live birth rate following ART in infertile Chinese Han women.**

Uterine anteroposterior diameter (mm)	No.	No. of live birth	Live birth rate (%)	RR (95% CI)*	aRR (95% CI)†
<30	115	94	81.7	1 (referent)	1 (referent)
30~	1503	1153	76.7	1.359 (0.834–2.213)	1.426 (0.870–2.338)
40~	3242	2470	76.2	1.399 (0.866–2.261)	1.444 (0.887–2.351)
≥50	2460	1806	73.4	1.621 (1.002–2.623)	1.636 (1.010–2.648)

* RR calculated from univariate binary logistic regression.

† RR calculated from multivariate binary logistic regression adjusted for number of previous ART treatments, total number of transferred embryos and the quality of transferred embryos.

suitable for the growth and development of the foetus. Of course, other factors have not been excluded, such as different methods of measurement.

Women with uterine widths of <30 mm or anteroposterior diameters of ≥50 mm experienced a lower likelihood of live birth, women with uterine widths closer to 50 mm and uterine anteroposterior diameters closer to 30 mm had the highest probability of live birth. Until now, no research has reported these probabilities of live birth for uterine widths and diameters.

The women with uterine volumes of <30 or ≥70 mL experienced a lower likelihood of live birth; women with a uterine volume closer to 50 mL had the highest probability of live birth. Previous studies focused on uterine volume related to non-cavity-distorting and cavity-distorting uterine fibroids and live birth rate.^[20–22] The relation between uterine volume and live birth rate following ART has not been published.

The potential mechanisms for a lower likelihood of live birth in women at the extremes of uterine size and volume may be multiple and complicated, including anatomical, hormonal, and genetic explanations. Though women with perceptible congenital abnormal uterus were excluded, extremes of uterine size and volume may signify anatomical variations that contribute to a decreased likelihood of implantation.^[14] Some studies documented a positive association between uterine size and estrone

concentration, which implied that the extremes of uterine size might reflect estrone deficiency or excess that adversely impacts on ART success,^[14,23,24] abnormal production or action of GH, progesterone and IGFs might affect it too.^[25,26] Furthermore, uterine size was influenced by the congenital abnormalities in *HOX* and *Wnt* gene expression.^[27]

The strength of our study first revealed their inherent relations between uterine size, volume and live birth outcome following ART in infertile women in Asia. These findings are more objective and credible because of sufficient sample size, accurate measurement, and adjustment for known confounders. These data may provide a reference for gynaecologists in the diagnosis and treatment of infertility.

The main limitation of the study is that we only studied infertile Chinese Han women and did not include a control group. The generalizability of our findings to other races and to the normal population remains unclear.

In conclusion, there were significant correlations between uterine size, volume, and live birth outcomes following ART in infertile women. The extremes of uterine lengths, widths, and volumes had the lowest live birth rate. Uterine size and volume that were too large or too small reduced live birth rates. Our findings may stimulate further research on the establishment of a prediction model based on uterine size and volume.

Table 6**Uterine volume and live birth rate following ART in infertile Chinese Han women.**

Uterine volume (mL)	No.	No. of live birth	Live birth rate (%)	RR (95% CI)*	aRR (95% CI)†
<30	690	504	73.0	1.229 (1.019–1.482)	1.368 (1.003–1.864)
30~	3191	2454	76.9	1 (referent)	1 (referent)
50~	2325	1778	76.5	1.024 (0.903–1.162)	1.161 (0.942–1.431)
≥70	1114	787	70.6	1.384 (1.187–1.612)	1.742 (1.360–2.232)

* RR calculated from univariate binary logistic regression.

† RR calculated from multivariate binary logistic regression adjusted for number of previous ART treatments, number of antral follicles, stimulation protocol, endometrial thickness before embryo transfer, total number of transferred embryos and the quality of transferred embryos.

Acknowledgments

The authors acknowledge the Guojun Wang, MD (Department of Social Medicine and Health Service Management, XiangYa School of Public Health) for proofreading this article and Xiao Gao, MD (Department of Epidemiology and Biostatistics, XiangYa School of Public Health) for assistance in the data analysis of this article.

Author contributions

Conceptualization: Hong Gao, Dong-e Liu, Hongzhan Tan.

Data curation: Hong Gao, Dong-e Liu.

Formal analysis: Hong Gao, Dong-e Liu, Hongzhan Tan.

Investigation: Hong Gao, Dong-e Liu, Yumei Li, Jing Tang, Hongzhan Tan.

Methodology: Hong Gao, Dong-e Liu, Yumei Li, Jing Tang, Xinrui Wu, Hongzhan Tan.

Project administration: Hong Gao, Dong-e Liu, Yumei Li, Jing Tang, Hongzhan Tan.

Resources: Hong Gao, Hongzhan Tan.

Software: Hong Gao, Xinrui Wu, Hongzhan Tan.

Supervision: Hong Gao, Dong-e Liu, Yumei Li, Jing Tang, Hongzhan Tan.

Validation: Hong Gao, Dong-e Liu, Hongzhan Tan.

Visualization: Hong Gao, Dong-e Liu, Hongzhan Tan.

Writing – original draft: Hong Gao.

Writing – review & editing: Hong Gao, Dong-e Liu, Hongzhan Tan.

References

- [1] Dyer S, Chambers GM, de Mouzon J, et al. International Committee for Monitoring Assisted Reproductive Technologies world report: Assisted Reproductive Technology 2008, 2009 and 2010. *Hum Reprod* 2016;31:1588–609.
- [2] Lee E, Chambers GM, Hale L, et al. Assisted reproductive technology (ART) cumulative live birth rates following preimplantation genetic diagnosis for aneuploidy (PGD-A) or morphological assessment of embryos: a cohort analysis. *Aust N Z J Obstet Gynaecol* 2018;5:525–32.
- [3] American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. Female age-related fertility decline. Committee Opinion No. 589. *Fertil Steril* 2014;101:633–4.
- [4] Menken J, Trussell J, Larsen U. Age and infertility. *Science* 1986;4771:1389–94.
- [5] Sunkara SK, La Marca A, Seed PT, et al. Increased risk of preterm birth and low birthweight with very high number of oocytes following IVF: an analysis of 65 868 singleton live birth outcomes. *Hum Reprod* 2015;6:1473–80.
- [6] Ulug U, Ben-Shlomo I, Turan E, et al. Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles. *Reprod Biomed Online* 2003;4:439–43.
- [7] Sunkara SK, Khalaf Y, Maheshwari A, et al. Association between response to ovarian stimulation and miscarriage following IVF: an analysis of 124 351 IVF pregnancies. *Hum Reprod* 2014;6:1218–24.
- [8] Giorgetti C, Terriou P, Auquier P, et al. Embryo score to predict implantation after in-vitro fertilization: based on 957 single embryo transfers. *Hum Reprod* 1995;9:2427–31.
- [9] Volpes A, Sammartano F, Coffaro F, et al. Number of good quality embryos on day 3 is predictive for both pregnancy and implantation rates in in vitro fertilization/intracytoplasmic sperm injection cycles. *Fertil Steril* 2004;5:1330–6.
- [10] Banerjee P, Choi B, Shahine LK, et al. Deep phenotyping to predict live birth outcomes in in vitro fertilization. *Proc Natl Acad Sci U S A* 2010;31:13570–5.
- [11] Prior M, Richardson A, Asif S, et al. Outcome of assisted reproduction in women with congenital uterine anomalies: a prospective observational study. *Ultrasound Obstet Gynecol* 2018;1:110–7.
- [12] Li X, Ouyang Y, Yi Y, et al. Pregnancy outcomes of women with a congenital unicornuate uterus after IVF-embryo transfer. *Reprod Biomed Online* 2017;5:583–91.
- [13] Ozgur K, Bulut H, Berkkanoglu M, et al. Reproductive outcomes of IVF patients with unicornuate uteri. *Reprod Biomed Online* 2017;3:312–8.
- [14] Hawkins LK, Correia KF, Srouji SS, et al. Uterine length and fertility outcomes: a cohort study in the IVF population. *Hum Reprod* 2013;11:3000–6.
- [15] Ledee N, Prat-Ellenber L, Chevrier L, et al. Uterine immune profiling for increasing live birth rate: a one-to-one matched cohort study. *J Reprod Immunol* 2017;119:23–30.
- [16] Gao H, Liu D, Li Y, et al. Uterine size and volume are associated with a higher clinical pregnancy rate in patients undergoing assisted reproduction technology. *Medicine* 2019;8:e14366.
- [17] Verguts J, Ameye L, Bourne T, et al. Normative data for uterine size according to age and gravidity and possible role of the classical golden ratio. *Ultrasound Obstet Gynecol* 2013;6:713–7.
- [18] Ben-Haroush A, Goldberg-Stern H, Phillip M, et al. GnRH agonist treatment in girls with precocious puberty does not compromise post-pubertal uterine size. *Hum Reprod* 2007;3:895–900.
- [19] Elder K, Brinsden PR. Routine gamete handling. *Textbook of In Vitro Fertilization and Assisted Reproduction: The Bourn Hall Guide to Clinical and Laboratory Practice* 3rd ed. London: Taylor & Francis; 2005;287–307.
- [20] Styer AK, Jin S, Liu D, et al. Association of uterine fibroids and pregnancy outcomes after ovarian stimulation-intrauterine insemination for unexplained infertility. *Fertil Steril* 2017;3:756–62.
- [21] Khalaf Y, Ross C, El-Toukhy T, et al. The effect of small intramural uterine fibroids on the cumulative outcome of assisted conception. *Hum Reprod* 2006;10:2640–4.
- [22] Somigliana E, De Benedictis S, Vercellini P, et al. Fibroids not encroaching the endometrial cavity and IVF success rate: a prospective study. *Hum Reprod* 2011;4:834–9.
- [23] Chua BH, Chua CC, Zhao ZY, et al. Estrone modulates the EGF receptor in the liver of db/db mouse. *J Recept Res* 1991;6:941–57.
- [24] Ciobanu LC, Luu-The V, Martel C, et al. Inhibition of estrone sulfate-induced uterine growth by potent nonestrogenic steroidal inhibitors of steroid sulfatase. *Cancer Res* 2003;19:6442–6.
- [25] Hull KL, Harvey S. Growth hormone: roles in female reproduction. *J Endocrinol* 2001;1:1–23.
- [26] Hart R, Sloboda DM, Doherty DA, et al. Prenatal determinants of uterine volume and ovarian reserve in adolescence. *J Clin Endocrinol Metab* 2009;12:4931–7.
- [27] Guerrier D, Mouchel To, Pasquier L, et al. The Mayer-Rokitansky-Kuster-Hauser syndrome (congenital absence of uterus and vagina) – phenotypic manifestations and genetic approaches. *J Negat Results Biomed* 2006;5:1–8.